These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 30877636

  • 1. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
    Manneh Kopp RA, Sepúlveda-Sánchez JM, Ruano Y, Toldos O, Pérez Núñez A, Cantero D, Hilario A, Ramos A, de Velasco G, Sánchez-Gómez P, Hernández-Laín A.
    Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
    [Abstract] [Full Text] [Related]

  • 2. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
    Cardona AF, Rojas L, Wills B, Ruiz-Patiño A, Abril L, Hakim F, Jiménez E, Useche N, Bermúdez S, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, Archila P, Rodríguez J, Rodríguez J, Behaine J, González D, Jacobo J, Cifuentes H, Feo O, Penagos P, Pineda D, Ricaurte L, Pino LE, Vargas C, Marquez JC, Mantilla MI, Ortiz LD, Balaña C, Rosell R, Zatarain-Barrón ZL, Arrieta O.
    Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
    [Abstract] [Full Text] [Related]

  • 3. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
    Seystahl K, Hentschel B, Loew S, Gramatzki D, Felsberg J, Herrlinger U, Westphal M, Schackert G, Thon N, Tatagiba M, Pietsch T, Reifenberger G, Löffler M, Wick W, Weller M, German Glioma Network.
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
    [Abstract] [Full Text] [Related]

  • 4. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
    Franceschi E, Lamberti G, Paccapelo A, Di Battista M, Genestreti G, Minichillo S, Mura A, Bartolini S, Agati R, Brandes AA.
    J Neurooncol; 2018 Sep; 139(2):383-388. PubMed ID: 29671196
    [Abstract] [Full Text] [Related]

  • 5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
    Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS.
    J Clin Oncol; 2017 Jan 20; 35(3):343-351. PubMed ID: 27918718
    [Abstract] [Full Text] [Related]

  • 6. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
    Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M.
    JAMA Oncol; 2020 Jul 01; 6(7):1003-1010. PubMed ID: 32437507
    [Abstract] [Full Text] [Related]

  • 7. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A.
    Neuro Oncol; 2015 Aug 01; 17(8):1139-47. PubMed ID: 25754089
    [Abstract] [Full Text] [Related]

  • 8. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
    Hovinga KE, McCrea HJ, Brennan C, Huse J, Zheng J, Esquenazi Y, Panageas KS, Tabar V.
    J Neurooncol; 2019 Apr 01; 142(2):337-345. PubMed ID: 30680510
    [Abstract] [Full Text] [Related]

  • 9. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
    Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Rudà R.
    J Neurooncol; 2014 Feb 01; 116(3):533-41. PubMed ID: 24293233
    [Abstract] [Full Text] [Related]

  • 10. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
    Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD.
    J Neurooncol; 2013 Nov 01; 115(2):267-76. PubMed ID: 23974656
    [Abstract] [Full Text] [Related]

  • 11. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
    Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O.
    J Neurooncol; 2016 Aug 01; 129(1):93-100. PubMed ID: 27193554
    [Abstract] [Full Text] [Related]

  • 12. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A, Schmitz AL, Knoll A, Schneider M, Hlavac M, König R, Wirtz CR, Coburger J.
    Clin Neurol Neurosurg; 2018 Apr 01; 167():6-10. PubMed ID: 29425743
    [Abstract] [Full Text] [Related]

  • 13. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A, Sepulveda JM, Hernandez-Lain A, Salvador E, Koren L, Manneh R, Ruano Y, Perez-Nuñez A, Lagares A, Ramos A.
    Clin Transl Oncol; 2017 Jan 01; 19(1):51-57. PubMed ID: 27026567
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
    George E, Kijewski MF, Dubey S, Belanger AP, Reardon DA, Wen PY, Kesari S, Horky L, Park MA, Huang RY.
    AJR Am J Roentgenol; 2018 Dec 01; 211(6):1342-1347. PubMed ID: 30332289
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.